Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2023 Aug 23

PMID 37608916

Authors

Carlos A Fierro

Michal Sarnecki

Joachim Doua

Bart Spiessens

Oscar Go

Todd A Davies

Germie van den Dobbelsteen

Jan Poolman

Darren Abbanat

Wouter Haazen

Affiliations

Soon will be listed here.

Abstract

Background: ExPEC10V is a bioconjugate vaccine containing O-antigen polysaccharides of 10 extraintestinal pathogenic (ExPEC) serotypes. This phase 1/2a study (NCT03819049) assessed the safety, reactogenicity, and immunogenicity of ExPEC10V (VAC52416) to prevent invasive disease in elderly adults.

Methods: The observer-blind, active-controlled design included a 28-day screening, vaccination, 181-day follow-up, and 1-year follow-up. Participants (60-85 years of age) were randomized to ExPEC10V low dose (antigen dose range, 4-8 µg), ExPEC10V medium dose (4-16 µg), or ExPEC10V high dose (8-16 µg); 4-valent ExPEC vaccine (ExPEC4V); or 13-valent pneumococcal conjugate vaccine (PCV13). The incidence of adverse events (AEs; solicited, day 15; unsolicited, day 30; serious AEs, day 181) and immunogenicity (electrochemiluminescent-based assay [ECL] and multiplex opsonophagocytic assay [MOPA]) were assessed. Optimal ExPEC10V dose was determined from safety data through day 30 and an immunogenicity dose selection algorithm based on day 15 ECL and MOPA results.

Results: A total of 416 participants were included (median age, 64.0 years; 54.8% female). The incidences of solicited local and systemic AEs were, respectively, 44.2% and 39.4% for low-dose, 52.9% and 46.1% for medium-dose, 57.7% and 45.2% for high-dose ExPEC10V, and 74.1% and 48.1% for PCV13. Five serious AEs, not vaccine related, were reported. The ECL revealed a robust antibody response to ExPEC10V through year 1. Opsonophagocytic killing activity was detected against all but serotype O8; this lack of response against serotype O8 was linked to low assay sensitivity. Based on the totality of data, high-dose ExPEC10V was considered optimal.

Conclusions: ExPEC10V was well tolerated and immunogenic in elderly adults against all but serotype O8.

Citing Articles

Recent advances in the biosynthesis of polysaccharide-based antimicrobial glycoconjugate vaccines.

Wang Y, Liu H, Wang B, Gheyret G, Qin J, Wang H Front Microbiol. 2025; 15:1457908.

PMID: 39943962 PMC: 11813929. DOI: 10.3389/fmicb.2024.1457908.

Economic and Disease Burden Associated with Invasive Escherichia coli Disease in the United States.

Schmidt M, Blum M, Donald J, Meenan R, Carrio E, Poolman J Infect Dis Ther. 2025; .

PMID: 39921800 DOI: 10.1007/s40121-025-01112-7.

A cynomolgus monkey urinary tract infection model confirms efficacy of new FimH vaccine candidates.

Chorro L, Ciolino T, Torres C, Illenberger A, Aglione J, Corts P Infect Immun. 2024; 92(10):e0016924.

PMID: 39297649 PMC: 11475676. DOI: 10.1128/iai.00169-24.

Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics.

Timm M, Russell S, Hultgren S Nat Rev Microbiol. 2024; 23(2):72-86.

PMID: 39251839 DOI: 10.1038/s41579-024-01092-4.

Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections.

Sauvat L, Verhoeven P, Gagnaire J, Berthelot P, Paul S, Botelho-Nevers E Clin Microbiol Rev. 2024; 37(3):e0016022.

PMID: 39120140 PMC: 11391692. DOI: 10.1128/cmr.00160-22.

References

Jackson L, Benson P, Neuzil K, Grandjean M, Marino J . Burden of community-onset Escherichia coli bacteremia in seniors. J Infect Dis. 2005; 191(9):1523-9. DOI: 10.1086/429344. View

Johnson J, Gajewski A, Lesse A, Russo T . Extraintestinal pathogenic Escherichia coli as a cause of invasive nonurinary infections. J Clin Microbiol. 2003; 41(12):5798-802. PMC: 309005. DOI: 10.1128/JCM.41.12.5798-5802.2003. View

Al-Hasan M, Lahr B, Eckel-Passow J, Baddour L . Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. J Antimicrob Chemother. 2009; 64(1):169-74. PMC: 2692504. DOI: 10.1093/jac/dkp162. View

Bou-Antoun S, Davies J, Guy R, Johnson A, Sheridan E, Hope R . Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014. Euro Surveill. 2016; 21(35). PMC: 5015457. DOI: 10.2807/1560-7917.ES.2016.21.35.30329. View

Laupland K, Church D . Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev. 2014; 27(4):647-64. PMC: 4187633. DOI: 10.1128/CMR.00002-14. View

Poolman J, Wacker M . Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field. J Infect Dis. 2015; 213(1):6-13. PMC: 4676548. DOI: 10.1093/infdis/jiv429. View

Cassini A, Plachouras D, Monnet D . Attributable deaths caused by infections with antibiotic-resistant bacteria in France - Authors' reply. Lancet Infect Dis. 2019; 19(2):129-130. DOI: 10.1016/S1473-3099(19)30004-0. View

de Kraker M, Jarlier V, Monen J, Heuer O, van de Sande N, Grundmann H . The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect. 2012; 19(9):860-8. DOI: 10.1111/1469-0691.12028. View

Sogaard M, Norgaard M, Dethlefsen C, Schonheyder H . Temporal changes in the incidence and 30-day mortality associated with bacteremia in hospitalized patients from 1992 through 2006: a population-based cohort study. Clin Infect Dis. 2010; 52(1):61-9. DOI: 10.1093/cid/ciq069. View

10.

Inoue M, Ogawa T, Tamura H, Hagiwara Y, Saito Y, Abbanat D . Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese.... Hum Vaccin Immunother. 2018; 14(9):2150-2157. PMC: 6183137. DOI: 10.1080/21645515.2018.1474316. View

11.

Melin M, Jarva H, Siira L, Meri S, Kayhty H, Vakevainen M . Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun. 2008; 77(2):676-84. PMC: 2632042. DOI: 10.1128/IAI.01186-08. View

12.

Doua J, Geurtsen J, Rodriguez-Bano J, Cornely O, Go O, Gomila-Grange A . Epidemiology, Clinical Features, and Antimicrobial Resistance of Invasive Disease in Patients Admitted in Tertiary Care Hospitals. Open Forum Infect Dis. 2023; 10(2):ofad026. PMC: 9933942. DOI: 10.1093/ofid/ofad026. View

13.

Al-Hasan M, Lahr B, Eckel-Passow J, Baddour L . Seasonal variation in Escherichia coli bloodstream infection: a population-based study. Clin Microbiol Infect. 2009; 15(10):947-50. PMC: 3938910. DOI: 10.1111/j.1469-0691.2009.02877.x. View

14.

Abernethy J, Johnson A, Guy R, Hinton N, Sheridan E, Hope R . Thirty day all-cause mortality in patients with Escherichia coli bacteraemia in England. Clin Microbiol Infect. 2015; 21(3):251.e1-8. DOI: 10.1016/j.cmi.2015.01.001. View

15.

. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655. PMC: 8841637. DOI: 10.1016/S0140-6736(21)02724-0. View

16.

Weerdenburg E, Davies T, Morrow B, Zomer A, Hermans P, Go O . Global Distribution of O Serotypes and Antibiotic Resistance in Extraintestinal Pathogenic Escherichia coli Collected From the Blood of Patients With Bacteremia Across Multiple Surveillance Studies. Clin Infect Dis. 2022; 76(3):e1236-e1243. PMC: 9907479. DOI: 10.1093/cid/ciac421. View

17.

Nolan K, Bonhomme M, Schier C, Green T, Antonello J, Murphy R . Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes. Bioanalysis. 2020; 12(14):1003-1020. DOI: 10.4155/bio-2020-0024. View

18.

Frenck Jr R, Ervin J, Chu L, Abbanat D, Spiessens B, Go O . Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. Lancet Infect Dis. 2019; 19(6):631-640. DOI: 10.1016/S1473-3099(18)30803-X. View

19.

Reinert R, Paradiso P, Fritzell B . Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines. 2010; 9(3):229-36. DOI: 10.1586/erv.10.6. View

20.

Huttner A, Hatz C, Dobbelsteen G, Abbanat D, Hornacek A, Frolich R . Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017; 17(5):528-537. DOI: 10.1016/S1473-3099(17)30108-1. View